vimarsana.com

Latest Breaking News On - University hospital regensburg - Page 1 : vimarsana.com

BioSenic provides support to forthcoming European conference on graft-versus-host disease

Mont-Saint-Guibert, Belgium, January 31, 2024, 7.00 am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it will attend and support the upcoming GvHGvL Meeting on 13-15 March, 2024 at University Hospital Regensburg, a biannual conference to lead scientific exchange around graft-versus-host disease (GvHD). GvHD can result from transplanting bone marrow or stem cells fr

Understanding AGAVE-201 and Unmet Need in Chronic GVHD

This article will appear in the January 2024 issue of Evidence-Based Oncology.™ Each year, our January issue features a recap of proceedings from the American Society of Hematology Meeting and Exposition.

Axatilimab Proves Highly Effective in Recurrent/Refractory Chronic GVHD

Axatilimab can produce durable responses in patients with recurrent or refractory chronic GVHD, a phase 2 trial suggests.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.